Biosimilar Launch Notification Delay Remains, Might Not Matter For Newer Products
This article was originally published in The Pink Sheet Daily
Executive Summary
In Amgen v Apotex, Federal Circuit says biosimilar applicants still need to wait for FDA approval to give reference product manufacturer launch notification regardless of patent dance status, but court suggests notice could be given upon tentative approval.
You may also be interested in...
Biosimilar Tentative Approvals Could Flow From US Supreme Court Case
If high court decides that biosimilar sponsors must wait until licensure before providing 180-day notice of commercial launch, FDA may face pressure to start granting tentative licenses for 351(k) applications, industry lawyer says.
Biosimilar Tentative Approvals Could Flow From US Supreme Court Case
If high court decides that biosimilar sponsors must wait until licensure before providing 180-day notice of commercial launch, FDA may face pressure to start granting tentative licenses for 351(k) applications, industry lawyer says.
Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip